The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 27692854 |
100 |
N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity. |
Boehringer Ingelheim Pharmaceuticals |
| 27096048 |
80 |
Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders. |
Peking Union Medical College and Chinese Academy of Medical Sciences |
| 26248802 |
46 |
Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability. |
Syntrix Biosystems |
| 25933594 |
6 |
Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model. |
Syntrix Biosystems |
| 25708618 |
30 |
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists. |
Astrazeneca |
| 24974342 |
33 |
The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists. |
Novartis Institutes For Biomedical Research |
| 25455491 |
32 |
2-Aminopyrimidin-4(1H)-one as the novel bioisostere of urea: discovery of novel and potent CXCR2 antagonists. |
Glaxosmithkline |
| 25254640 |
64 |
Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. |
Syntrix Biosystems |
| 23516963 |
99 |
Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1). |
Astrazeneca |
| 22931505 |
69 |
Chemokine receptor antagonists. |
National Heart and Lung Institute |
| 17483457 |
58 |
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. |
Abbott Laboratories |
| 18240390 |
27 |
Evaluation of a series of bicyclic CXCR2 antagonists. |
Astrazeneca R&D Charnwood |
| 18308567 |
44 |
Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor. |
Johnson & Johnson Pharmaceutical Research and Development |
| 17236763 |
39 |
Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. |
Glaxosmithkline |
| 17181143 |
31 |
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. |
Schering-Plough Research Institute |
| 15357956 |
11 |
Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor. |
Glaxosmithkline |
| 21341682 |
37 |
Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. |
Telik |
| 20591666 |
66 |
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase. |
Università |
| 20297846 |
33 |
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. |
Genzyme |
| 19713110 |
27 |
Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists. |
Wuxi Pharmatech |
| 19525110 |
46 |
Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region. |
Schering-Plough Research Institute |
| 19200721 |
50 |
3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists. |
Schering-Plough Research Institute |
| 19196511 |
42 |
Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists. |
Schering-Plough Research Institute |
| 18304809 |
24 |
Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists. |
Pharmacopeia |
| 18242983 |
82 |
Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists. |
Schering-Plough Research Institute |
| 18006311 |
40 |
3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists. |
Schering-Plough Research Institute |
| 17524641 |
69 |
3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists. |
Glaxosmithkline |
| 17459706 |
42 |
C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists. |
Schering-Plough Research Institute |
| 16934456 |
36 |
N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors. |
Glaxosmithkline |
| 16697193 |
26 |
Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists. |
Pharmacopeia Drug Discovery |
| 16540318 |
28 |
Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists. |
Pharmacopeia Drug Discovery |
| 16297626 |
14 |
Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. |
Astrazeneca R&D Charnwood |
| 15771462 |
125 |
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. |
Pharmaceutical Research Institute |
| 14998320 |
16 |
Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. |
Glaxosmithkline |
| 12873480 |
30 |
Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists. |
Astrazeneca R&D Charnwood |
| 12031332 |
27 |
Nicotinanilides as inhibitors of neutrophil chemotaxis. |
Celltech R&D |
| 11459668 |
16 |
Nicotinamide N-oxides as CXCR2 antagonists. |
Celltech R&D |
| 31732253 |
20 |
Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead. |
Hangzhou Institute of Innovative Medicine |
| 30106578 |
10 |
Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts. |
TBA |
| 24332493 |
33 |
The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists. |
Novartis Institutes For Biomedical Research |
| 23409871 |
48 |
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists. |
Glaxosmithkline |
| 29631962 |
252 |
Identification and biological evaluation of thiazole-based inverse agonists of ROR?t. |
Phenex Pharmaceuticals |
| 29406702 |
128 |
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists. |
Gsk Pharmaceuticals R & D |
| 3208837 |
3 |
2',3'-Dideoxy-N6-cyclohexyladenosine: an adenosine derivative with antagonist properties at adenosine receptors. |
Pharmakologisches Institut |
| 16950396 |
13 |
Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes. |
Osaka University of Pharmaceutical Sciences |
Search and Browse
